Our Leadership

With over 25 years of commercial expertise spanning the pharmaceutical, biotech, and medical devices sectors, Robert brings unparalleled leadership to his role as Co-founder & CEO.

 

Renowned for his adeptness in navigating complex landscapes, Robert has spearheaded the successful commercialization of products within both large corporations and nimble startups across diverse therapeutic areas. His proficiency extends from prelaunch strategizing to executing impactful market entries, both domestically and on the global stage.

​

Prior to founding SANTANDER Pharma Consulting, Robert served as the Chief Commercial Officer at Bryn Pharma, where he orchestrated transformative initiatives across marketing, sales, commercial operations, and strategic partnerships. Robert’s illustrious career features leadership positions at esteemed organizations including GlaxoSmithKline, Johnson & Johnson, Merz Pharmaceuticals, XenoPort, Inc., BioDelivery Sciences, Circassia Pharmaceuticals, and Bryn Pharma, each contributing to his rich tapestry of expertise and achievements.

​

Robert’s academic journey is marked by a commitment to excellence. He earned his B.A. in International Business from San Jose State University and further honed his strategic acumen with an MBA in Strategy Development and Execution from Pepperdine University. His relentless pursuit of innovation and excellence continues to drive him forward, shaping the future of the industry and empowering teams to achieve unprecedented success.

Michelle is a senior financial executive with over 25 years of experience in public and privately held biotech, pharmaceutical, and life science companies. Michelle’s experience includes a broad range of responsibilities in a highly complex and regulated market. She also brings deep corporate governance experience through her work with corporate boards, including audit, compensation, nominating & governance and finance committees.

​

Michelle serves as the Chief Financial Officer of MIRA Pharmaceuticals (Nasdaq: MIRA) since April 2023, which is a publicly traded pre-clinical-stage pharmaceutical development company with neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders.

 

Since June 2024, Michelle also serves as Chief Financial Officer of Telomir Pharmaceuticals (Nasdaq: TELO), a publicly traded pre-clinical-stage pharmaceutical development company, focusing on the development and commercialization of therapeutic treatment for human stem cells for human and animal uses.

​​

From May 2002 until its acquisition in April 2022, Michelle held various leadership positions at BioDelivery Sciences International, Inc. (Nasdaq: BDSI). In her role, she led financial offerings, managed due diligence for product acquisitions and financings and managed finance documents and filings for the tender offer, leading to the acquisition of BDSI in April 2022. Michelle also serves as a non-employee director of Inhibitor Therapeutics, Inc. (OTCQB: INTI), a publicly traded pharmaceutical development company focused on therapeutics for certain cancers and non-cancerous proliferation disorders, since December 2022.

​

Michelle earned her B.A. in Business Management from University South Florida and further distinguished her acumen with an MBA in Strategic Leadership from Rutgers School of Business, Cum Laude.